OC
VIRX

Oppenheimer & Co’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Oppenheimer & Co’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38,037
Closed -$305K – 1588
2021
Q3 		$305K Buy
+38,037
New +$375K 0.01% 1219

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co's VIRX Position: Q4 2021 in Review

Oppenheimer & Co sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 38,037 shares — an estimated $305K sold.

Oppenheimer & Co first reported a position in VIRX in Q3 2021 and held it in 1 quarter. The position peaked at $305K in Q3 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • Oppenheimer & Co reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 38,037 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $305K.
  • Oppenheimer & Co first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Oppenheimer & Co's Viracta Therapeutics, Inc. Common Stock position peaked at $305K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.